Bimekizumab in Psoriasis: 3-Year Outcomes
Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.
By
Kathryn Wighton
March 12, 2026
Clinical Scorecard: Bimekizumab in Psoriasis: 3-Year Outcomes
At a Glance
Category Detail
Condition Moderate to severe plaque psoriasis Key Mechanisms Bimekizumab targets IL-17A and IL-17F, leading to rapid symptom relief and improved quality of life. Target Population Adults with moderate to severe plaque psoriasis Care Setting Multicenter, randomized clinical trial
Key Highlights
Significant improvement in symptoms reported as early as week 4. At year 3, 62.2% of continuous bimekizumab patients achieved PASI 0 and DLQI 0 or 1. Bimekizumab showed higher rates of symptom resolution compared to secukinumab at multiple time points. Guideline-Based Recommendations
Diagnosis
Diagnosis of psoriasis should be based on clinical evaluation and patient history. Management
Bimekizumab is recommended for patients with moderate to severe plaque psoriasis. Monitoring & Follow-up
Regular assessment of symptoms and quality of life using validated tools like PASI and DLQI. Risks
Consider potential treatment-related adverse events and lack of efficacy as reasons for discontinuation. Patient & Prescribing Data
743 patients with moderate to severe plaque psoriasis
Bimekizumab administered at 320 mg every 4 weeks for 16 weeks, then every 8 weeks.
Clinical Best Practices
Utilize patient-reported outcome measures to assess treatment effectiveness. Monitor for comorbid conditions that may affect treatment outcomes. Related Resources & Content
